{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-24-013486","form_type":"8-K","ticker":"APRE","cik":"0001781983","company_name":"Aprea Therapeutics, Inc.","filed_at":"2024-10-23T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.588011+00:00","generated_at":"2026-05-30T11:08:16.756620+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Aprea reports preliminary Phase 1 safety data for WEE1 inhibitor APR-1051; no hematologic toxicity","bullets":["APR-1051 safe and well-tolerated in first three patients; all adverse events Grade 1-2, no neutropenia or QT prolongation.","Phase 1 ACESOT-1051 study evaluating 10–150 mg daily doses; 8 cohorts planned, subtherapeutic doses given in cohorts 1-3.","Data cutoff Oct 7, 2024: one patient progressed at 49 days, one withdrew at 36 days, third continues on treatment.","Active enrollment at 3 U.S. sites (NEXT Oncology in San Antonio & Dallas, MD Anderson); preliminary efficacy data expected in 2025.","APR-1051 designed for selective WEE1 inhibition without PLK off-target effects seen with other WEE1 inhibitors."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-24-013486","json":"https://secwatch.observer/filing/0001558370-24-013486.json","markdown":"https://secwatch.observer/filing/0001558370-24-013486.md","text":"https://secwatch.observer/filing/0001558370-24-013486.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1781983/000155837024013486/0001558370-24-013486-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1781983/000155837024013486/apre-20241023x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T11:08:16.756620+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}